Vasopressin beyond water: Implications for renal diseases

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 499-504

  Bolignano, Davide ^a   Zoccali, Carmine ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

chronic kidney disease; copeptin; vasopressin; vasopressin receptor antagonists; vasopressin receptors

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; COPEPTIN; ENALAPRIL; LOSARTAN; MOZAVAPTAN; RWJ 676070; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST;

CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; EXTRACELLULAR MATRIX; FLUID INTAKE; GLOMERULOSCLEROSIS; HUMAN; KIDNEY; KIDNEY INJURY; MESANGIUM CELL; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; REVIEW;

ANIMALS; ARGININE VASOPRESSIN; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; GLYCOPEPTIDES; HUMANS; KIDNEY DISEASES; MESANGIAL CELLS; RECEPTORS, VASOPRESSIN; RENAL CIRCULATION;

EID: 77955922264     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833d35cf     Document Type: Review

References (50)

1. Sands JM, Layton HE. The physiology of urinary concentration: an update. Semin Nephrol 2009; 29:178-195.
2. Egashira N, Mishima K, Iwasaki K, et al. New topics in vasopressin receptors and approach to novel drugs: role of the vasopressin receptor in psychological and cognitive functions. J Pharmacol Sci 2009; 109:44-49.
3. Arpin-Bott MP, Kaissling B, Waltisperger E, et al. Historadioautographic localization of oxytocin and V1a vasopressin binding sites in the kidney of developing and adult rabbit, mouse and merione and of adult human. Exp Nephrol 2002; 10:196-208.
4. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989; 256 (2 Pt 2):F274-F278.
5. Pallone TL, Robertson CR, Jamison RL. Renal medullary microcirculation. Physiol Rev 1990; 70:885-920.
6. Bouby N, Ahloulay M, Nsegbe E, et al. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7:842-851.
7. Gellai M, Silverstein JH, Hwang JC, et al. Influence of vasopressin on renal hemodynamics in conscious Brattleboro rats. Am J Physiol 1984; 246(6 Pt 2): F819-F827.
8. Armsen T, Reinhardt HW. Transtubular movement of urea at different degrees of water diuresis. Pflugers Arch 1971; 326:270-280.
9. Bouby N, Trinh-Trang-Tan MM, Laouari D, et al. Role of the urinary concentrating process in the renal effects of high protein intake. Kidney Int 1988; 34:4-12.
10. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258 (4 Pt 2):F973-F979.
11. Sugiura T, Yamauchi A, Kitamura H, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: possible role of TGF-beta. Kidney Int 1999; 55:1800-1810.
12. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfil-tration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci\USA 1999; 96:10397-10402.
13. Yamada K, Nakano H, Nishimura M, Yoshida S. Effect of AVP.V1-receptor antagonist on urinary albumin excretion and renal hemodynamics in NIDDM nephropathy: role of AVP.V1-receptor. J Diabetes Complications 1995; 9:326-329.
14. Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18:497-506.
15. Schweda F, Klar J, Narumiya S, et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys. Am J Physiol Renal Physiol 2004; 287:F427-F433.
16. Martin PY, Bianchi M, Roger F, et al. Arginine vasopressin modulates expression of neuronal NOS in rat renal medulla. Am J Physiol Renal Physiol 2002; 283:F559-F568.
17. Takeuchi K, Yanai N, Takahashi N, et al. Different cellular mechanisms of vasopressin receptor V1 and V2 subtype in vasopressin-induced adenosine 3', 5'-monophosphate formation in an immortalized renal tubule cell line, TKC2. Biochem Biophys Res Commun 1994; 202:680-687.
18. Aoyagi T, Izumi Y, Hiroyama M, et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol 2008; 295:F100-F107.
19. Ganz MB, Pekar SK, Perfetto MC, Sterzel RB. Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture. Am J Physiol 1988; 255 (5 Pt 2):F898-F906.
20. Kusaka I, Ishikawa SE, Higashiyama M, et al. The activation of phospholipase D participates in the mitogenic action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 1996; 137:5421-5428.
21. Schulze-Lohoff E, Kohler M, Fees H, et al. Divergent effects of arginine vasopressin and angiotensin II on proliferation and expression of the immediate early genes c-fos, c-jun and Egr-1 in cultured rat glomerular mesangial cells. J Hypertens 1993; 11:127-134.
22. Higashiyama M, Ishikawa S, Saito T, et al. Arginine vasopressin inhibits apoptosis of rat glomerular mesangial cells via V1a receptors. Life Sci 2001; 68:1485-1493.
23. Tahara A, Tsukada J, Tomura Y, et al. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells. Eur J Pharmacol 2006; 538:32-38.
24. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol 2001; 280:F972-F979.
25. WolthuisA, Boes A, Rodemann HP, Grond J. Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells. Kidney Int 1992; 41:124-131.
26. Bakris GL, Fairbanks R, Traish AM. Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 1991; 87:1158-1164.
27. Tahara A, Tsukada J, Tomura Y, et al. Vasopressin stimulates the production of extracellular matrix by cultured rat mesangial cells. Clin Exp Pharmacol Physiol 2008; 35:586-593.
28. Tahara A, Tsukada J, Tomura Y, et al. Vasopressin increases type IV collagen production through the induction of transforming growth factor-beta secretion in rat mesangial cells. Pharmacol Res 2008; 57:142-150.
29. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5 (2 Pt 2):I129-I138.
30. Fenske W, Stork S, Blechschmidt A, et al. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94:123-129.
31. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009; 116:257-263.
32. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115:2103-2110.
33. Voors AA, von Haehling S, Anker SD, et al., OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30:1187-1194.
34. Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36:771-778.
35. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008; 14: 739-745.
36. Meijer E, Bakker SJ, Halbesma N, et al. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010; 77:29-36.
37. MaierC, Clodi M, Neuhold S, etal. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009; 32:1890-1895.
38. Meijer E, Bakker SJ, De Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009; 88:561-567.
39. Bolignano D, Coppolino G, Criseo M, etal. Aquaretic agents: what's beyond the treatment of hyponatremia? Curr Pharm Des 2007; 13:865-871.
40. Belibi FA, ReifG, Wallace DP, etal. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. Kidney Int 2004; 66:964-973.
41. Torres VE. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis 2010; 17:190-204.
42. Okada H, Suzuki H, Kanno Y, Saruta T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron 1996; 72:667-672.
43. Windt WA, Tahara A, Kluppel AC, et al. Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy. J Renin Angiotensin Aldosterone Syst 2006; 7:217-224.
44. Okada H, Suzuki H, Kanno Y, Saruta T. Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats. J Cardiovasc Pharmacol 1995; 25:847-852.
45. Kurihara I, Saito T, Obara K, et al. Effect of a nonpeptide vasopressin V1 antagonist (OPC-21268) on experimental accelerated focal glomerulosclerosis. Nephron 1996; 73:629-636.
46. Otsuka F, Ogura T, Yamauchi T, et al. Effects of OPC-21268, a vasopressin V1-receptor antagonist, on expression of growth factors from glomeruli in spontaneously hypertensive rats. Regul Pept 1997; 72:87-95.
47. BardouxP, Bruneval P, Heudes D, etal. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18:1755-1763.
48. Okada T, Sakaguchi T, Hatamura I, et al. Tolvaptan, a selective oral vaso-pressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. Clin Exp Nephrol 2009; 13:438-446.
49. Perico N, Zoja C, Corna D, et al. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int 2009; 76:960-967.
50. Hebert LA, Greene T, Levey A, et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41:962-971.